Skip to content
Study details
Enrolling now

FT836 Trial

Fate Therapeutics
NCT IDNCT07216105ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

113

Study length

about 4.2 years

Ages

18+

Locations

5 sites in CA, MN, PA +1

What this study is about

This trial is testing FT836, a medication, in people with advanced solid tumors. The goal is to see if FT836 is safe and well-tolerated when used alone or with other medications like paclitaxel, trastuzumab, or cetuximab.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cetuximab
  • 2.Take FT836
  • 3.Take Paclitaxel
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cetuximab, paclitaxel (Taxane chemotherapy; stabilizes microtubules), trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells)

Drug routes

injection (Injection), injection, intravenous

Endpoints

Primary: Number of participants with dose limiting toxicities (DLTs)

Secondary: Duration of Response (DOR), Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS)

Body systems

Oncology